Drug Profile
Research programme: nonsteroidal anti-inflammatory drugs sublingual - Kedem Pharmaceuticals
Alternative Names: Sublingual naproxenLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Global Health Ventures
- Developer Kedem Pharmaceuticals
- Class Nonsteroidal anti-inflammatories
- Mechanism of Action Cyclooxygenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Musculoskeletal disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Musculoskeletal-disorders in Canada (Sublingual)
- 07 Nov 2011 Global Health Ventures is now called Kedem Pharmaceuticals
- 13 Jul 2011 Early research in Musculoskeletal disorders in Canada (Sublingual)